|
Parameter
|
Parameter/ category
|
7-days mortality (stepwise)
|
In-hospital mortalitya
|
|---|
|
HR
|
CI95
|
P-value
|
HR
|
CI95
|
P-value
|
|---|
|
Interaction effect between pathogen species and ESBL-production
|
E. coli ESBL-negative
|
1 = Reference
| |
0.947
|
1 = Reference
| |
0.084
|
|
E. coli ESBL-positive
|
1.16
|
0.70–1.90
|
0.571
|
1.22
|
0.88–1.68
|
0.228
|
|
K. pneumoniae ESBL-negative
|
0.98
|
0.64–1.50
|
0.926
|
1.39
|
1.07–1.82
|
0.015
|
|
K. pneumoniae ESBL-positive
|
1.05
|
0.49–2.27
|
0.894
|
1.01
|
0.60–1.67
|
0.983
|
|
Comorbidities
|
Heart disease
|
1.55
|
1.09–2.21
|
0.014
|
1.23
|
0.97–1.56
|
0.087
|
|
Liver disease
|
1.96
|
1.40–2.74
|
<0.001
|
1.85
|
1.48–2.30
|
<0.001
|
|
Renal disease
|
2.86
|
1.99–4.10
|
<0.001
|
2.32
|
1.82–2.95
|
<0.001
|
|
Cancer/ immunological disease
|
1.66
|
1.21–2.28
|
0.002
|
1.58
|
1.28–1.95
|
<0.001
|
-
ESBL extended-spectrum beta-lactamase, HR hazard ratio, CI95 95 % confidence interval, N.s. not significant
-
aAnalyzing the same parameters as in 7-days mortality
-
P-values <0.05 were considered statistically significant
